Jim Simons’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26M | Buy |
3,759,559
+378,598
| +11% | +$2.92M | 0.04% | 556 |
|
|
2025
Q4 | $29.8M | Sell |
3,380,961
-95,964
| -3% | -$528K | 0.05% | 454 |
|
|
2025
Q3 | $17.3M | Buy |
3,476,925
+29,465
| +0.9% | +$136K | 0.02% | 801 |
|
|
2025
Q2 | $16.3M | Sell |
3,447,460
-118,965
| -3% | -$520K | 0.02% | 804 |
|
|
2025
Q1 | $16.4M | Sell |
3,566,425
-287,374
| -7% | -$1.34M | 0.02% | 748 |
|
|
2024
Q4 | $18.5M | Sell |
3,853,799
-157,723
| -4% | -$757K | 0.03% | 708 |
|
|
2024
Q3 | $18.8M | Sell |
4,011,522
-102,603
| -2% | -$550K | 0.03% | 701 |
|
|
2024
Q2 | $23.2M | Sell |
4,114,125
-161,500
| -4% | -$834K | 0.04% | 536 |
|
|
2024
Q1 | $17.6M | Buy |
4,275,625
+594,500
| +16% | +$2.38M | 0.03% | 695 |
|
|
2023
Q4 | $15.5M | Buy |
3,681,125
+415,100
| +13% | +$1.67M | 0.02% | 729 |
|
|
2023
Q3 | $14.1M | Buy |
3,266,025
+153,958
| +5% | +$855K | 0.02% | 732 |
|
|
2023
Q2 | $20.5M | Buy |
3,112,067
+176,842
| +6% | +$1.13M | 0.03% | 663 |
|
|
2023
Q1 | $19.9M | Buy |
2,935,225
+45,800
| +2% | +$322K | 0.03% | 717 |
|
|
2022
Q4 | $21.4M | Sell |
2,889,425
-405,808
| -12% | -$3.95M | 0.03% | 678 |
|
|
2022
Q3 | $32.6M | Sell |
3,295,233
-341,200
| -9% | -$3.6M | 0.05% | 457 |
|
|
2022
Q2 | $39.6M | Buy |
3,636,433
+427,819
| +13% | +$4.43M | 0.05% | 434 |
|
|
2022
Q1 | $36.3M | Sell |
3,208,614
-3,600
| -0.1% | -$47.3K | 0.04% | 454 |
|
|
2021
Q4 | $50.4M | Sell |
3,212,214
-70,108
| -2% | -$1.22M | 0.06% | 336 |
|
|
2021
Q3 | $56.3M | Sell |
3,282,322
-28,600
| -0.9% | -$501K | 0.07% | 284 |
|
|
2021
Q2 | $71.2M | Sell |
3,310,922
-375,558
| -10% | -$6.72M | 0.09% | 233 |
|
|
2021
Q1 | $55.4M | Sell |
3,686,480
-303,923
| -8% | -$4.92M | 0.07% | 313 |
|
|
2020
Q4 | $52.4M | Sell |
3,990,403
-390,519
| -9% | -$4.7M | 0.06% | 331 |
|
|
2020
Q3 | $42.3M | Buy |
4,380,922
+151,100
| +4% | +$1.62M | 0.04% | 434 |
|
|
2020
Q2 | $48.4M | Buy |
4,229,822
+380,168
| +10% | +$4.3M | 0.04% | 439 |
|
|
2020
Q1 | $39.9M | Buy |
3,849,654
+396,542
| +11% | +$4.92M | 0.04% | 458 |
|
|
2019
Q4 | $56.7M | Buy |
3,453,112
+244,772
| +8% | +$3.7M | 0.04% | 476 |
|
|
2019
Q3 | $42.6M | Buy |
3,208,340
+410,290
| +15% | +$5.72M | 0.04% | 564 |
|
|
2019
Q2 | $39.4M | Buy |
2,798,050
+233,300
| +9% | +$3.71M | 0.03% | 591 |
|
|
2019
Q1 | $47.2M | Buy |
2,564,750
+53,400
| +2% | +$1.22M | 0.04% | 539 |
|
|
2018
Q4 | $65.6M | Buy |
2,511,350
+462,700
| +23% | +$10.9M | 0.07% | 314 |
|
|
2018
Q3 | $47M | Buy |
2,048,650
+367,400
| +22% | +$7.5M | 0.05% | 467 |
|
|
2018
Q2 | $32M | Buy |
1,681,250
+41,200
| +3% | +$689K | 0.03% | 647 |
|
|
2018
Q1 | $27.6M | Buy |
1,640,050
+205,200
| +14% | +$3.43M | 0.03% | 752 |
|
|
2017
Q4 | $21.8M | Buy |
1,434,850
+216,600
| +18% | +$3.21M | 0.02% | 886 |
|
|
2017
Q3 | $21.8M | Buy |
1,218,250
+120,300
| +11% | +$2.01M | 0.03% | 841 |
|
|
2017
Q2 | $17.9M | Buy |
1,097,950
+158,700
| +17% | +$2.29M | 0.02% | 918 |
|
|
2017
Q1 | $13.2M | Buy |
939,250
+370,900
| +65% | +$5.29M | 0.02% | 1061 |
|
|
2016
Q4 | $9.06M | Buy |
568,350
+136,300
| +32% | +$2.19M | 0.01% | 1295 |
|
|
2016
Q3 | $7.19M | Buy |
432,050
+281,000
| +186% | +$3.78M | 0.01% | 1381 |
|
|
2016
Q2 | $1.69M | Sell |
151,050
-265,850
| -64% | -$2.57M | ﹤0.01% | 2300 |
|
|
2016
Q1 | $3.48M | Buy |
416,900
+79,510
| +24% | +$653K | 0.01% | 1881 |
|
|
2015
Q4 | $3.14M | Buy |
+337,390
| New | +$3.37M | 0.01% | 1808 |
|
|
2015
Q2 | – | Sell |
-195,100
| Closed | -$1.81M | – | 3400 |
|
|
2015
Q1 | $1.81M | Buy |
+195,100
| New | +$2.2M | ﹤0.01% | 1985 |
|
|
2013
Q4 | – | Sell |
-256,600
| Closed | -$2.81M | – | 3041 |
|
|
2013
Q3 | $2.81M | Sell |
256,600
-97,529
| -28% | -$1.04M | 0.01% | 1495 |
|
|
2013
Q2 | $2.86M | Buy |
+354,129
| New | +$2.38M | 0.01% | 1390 |
|
Other funds holding VNDA
ACM
VCM
Jim Simons's VNDA Position: Q1 2026 in Review
Jim Simons increased its Vanda Pharmaceuticals (VNDA) stake by 11% in Q1 2026, buying an estimated $2.92M and bringing the position to 3,759,559 shares worth $26M. The position accounts for 0.04% of the portfolio, ranked #556.
Jim Simons first reported a position in VNDA in Q2 2013 and has held it in 45 quarters since. The position peaked at $71.2M in Q2 2021. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.
- Jim Simons held 3,759,559 shares of Vanda Pharmaceuticals worth $26M as of Q1 2026.
- Jim Simons bought 378,598 Vanda Pharmaceuticals shares in Q1 2026, an estimated $2.92M.
- Vanda Pharmaceuticals made up 0.04% of Jim Simons's portfolio in Q1 2026, its #556 holding.
- Jim Simons first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- Jim Simons's Vanda Pharmaceuticals position peaked at $71.2M in Q2 2021.
- 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.